ArticleSao Paulo medical journal = Revista paulista de medicina2020
Translation, cross-cultural adaptation and validation of the Finnish Diabetes Risk Score (FINDRISC) for use in Brazilian Portuguese: questionnaire validity study.
Article in Sao Paulo medical journal = Revista paulista de medicina, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 10 citations in OpenAlex.
- Assessing the Risk of Type 2 Diabetes Among University Employees in Kuwait: A Cross-Sectional Study.International journal of environmental research and public health · 2026Article
- Effect of HIIT Training Modality in People with Pre-Diabetes.Journal of functional morphology and kinesiology · 2026Article
- Assessing Type 2 Diabetes Risk in the Post-Pandemic Era: A Pharmacy-Led FINDRISC Screening Study.Life (Basel, Switzerland) · 2024Article
- Arabic version of the Australian type 2 diabetes risk assessment tool (AUSDRISK): translation and validation.BMC research notes · 2022Article
- Spanish language version of the "Medical Quality Video Evaluation Tool" (MQ-VET): Cross-cultural AI-supported adaptation and validation study.Science progressArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Finnish Diabetes Risk Score (FINDRISC) is a questionnaire that was developed by Finnish researchers to track the risk of diabetes.
objectiveTo translate, cross-culturally adapt and validate the FINDRISC for use in Brazilian Portuguese. DESIGN AND
settingQuestionnaire validity study conducted at a private university.
methodsThe Brazilian version of the FINDRISC was developed through the processes of translation, back-translation, committee review and pre-testing. Test-retest reliability was measured using the intraclass correlation coefficient (ICC), kappa coefficient, standard error of measurement (SEM) and minimum detectable change (MDC). Internal consistency was measured using Cronbach's alpha. For construct validity, the total score of the FINDRISC was correlated with the Diabetes Knowledge Scale (DKN-A) and Diabetes Mellitus Risk Questionnaire (QRDM). Ceiling and floor effects were also evaluated in the present study.
resultsFor construct validity and floor and ceiling effect measurements, a total sample of 107 participants was used. For reliability, a subsample of 51 participants out of the total sample was used. We identified adequate values for reliability (kappa ≥ 0.79 and ICC = 0.98) and internal consistency (Cronbach's alpha = 0.84). Regarding the error inherent in the FINDRISC, we found SEM = 8.02% and MDC = 22.44%. There were significant correlations between the FINDRISC and the QRDM (r = 0.686) and DKN-A (r = -0.216). No ceiling or floor effects were found.
conclusionThe Brazilian version of the FINDRISC has adequate psychometric properties that are in accordance with the best international recommendations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.